Page 2 - கிறிஸ்டன் க்லுஸ்கா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கிறிஸ்டன் க்லுஸ்கா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கிறிஸ்டன் க்லுஸ்கா Today - Breaking & Trending Today

Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript

Operator
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics First Quarter 2021 Financial Results Conference Call and Webcast. [Operator Instructions]
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Head of Investor Relations. You may begin.
Andrew Faughnan
Thank you, Mary.
Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics first quarter 2021 financial results and corporate highlights.
Speaking on today s call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A, we ll have Dr. Mitchell Goldman, Senior Vice President of Clinical Research joining. ....

United States , University Of Pennsylvania , Mitchell Goldman , Fisher Brammer , Anupam Rama , Salveen Richter Goldman Sachs , Debjit Chattopadhyay , Mohit Bansal Citigroup , Bradley Campbell , Salveen Richter , Daphne Quimi , Andrew Faughnan , Kristen Kluska , Kristen Kluska Cantor Fitzgerald , Jim Wilson , Sanofi Genzyme , Jeff Castelli , Sebastien Martel , John Crowley , Tessa Romero Jpmorgan , Tazeen Ahmad , Mohit Bansal , Joseph Schwartz , Development Officer , Goldman Sachs , Amicus Therapeutics Inc ,

CSL closes deal for UniQure gene therapy in hopeful sign for M&A

Dive Brief:
UniQure said Thursday it closed a deal with CSL Behring, selling an experimental gene therapy for hemophilia B after regulators in three countries signed off on the transaction.
By May 13, UniQure will receive $450 million from CSL, and could take home as much as $1.6 billion in additional payments contingent on reaching certain regulatory and commercial milestones. The Dutch biotech will also be reimbursed for the costs of development and regulatory activities undertaken during the transfer of responsibilities to CSL.
The deal s clearance is the latest indication that biopharma dealmaking may not yet be slowed by the Federal Trade Commission s plans to look more closely at acquisitions. Concern that the FTC may hold up the alliance weighed down UniQure s shares, according to some Wall Street analysts. The company s stock climbed 7% in trading Thursday. ....

Kristen Kluska , Paul Matteis , Cantor Fitzgerald , Drug Administration , Dive Brief , Federal Trade Commission , Wall Street , Spark Therapeutics , கிறிஸ்டன் க்லுஸ்கா , பால் மாத்தேச் , கேன்டர் ஃபிட்ஸ்‌ஜெரல்ட் , டைவ் சுருக்கமான , கூட்டாட்சியின் வர்த்தகம் தரகு , சுவர் தெரு , தீப்பொறி சிகிச்சை ,

Why Amicus Therapeutics Stock Is Soaring Today

Why Amicus Therapeutics Stock Is Soaring Today
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.

Kristen Kluska , Cantor Fitzgerald Kluska , Amicus Therapeutics , Cantor Fitzgerald , European Union , கிறிஸ்டன் க்லுஸ்கா , அமிகஸ் சிகிச்சை , கேன்டர் ஃபிட்ஸ்‌ஜெரல்ட் , ஐரோப்பிய தொழிற்சங்கம் ,

HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today

Heat Biologics (HTBX) stock is heating up on Wednesday following new coverage from Cantor Fitzgerald analyst Kristen Kluska.More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now ....

North Carolina , United States , Kristen Kluska , Bukhta Yurii Shutterstock , Cantor Fitzgerald , Bukhta Yurii , Heat Biologics , வடக்கு கரோலினா , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டன் க்லுஸ்கா , கேன்டர் ஃபிட்ஸ்‌ஜெரல்ட் , வெப்பம் உயிரியல் ,

Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript

Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Amicus Therapeutics Inc (NASDAQ: FOLD)
Popular Searches
Operator
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Fourth Quarter 2020 Fiscal Year Results Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Head of Investor Relations. You may begin.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company s SEC filings. Please ....

United States , University Of Pennsylvania , Mitchell Goldman , Anupam Rama , Bradleyl Campbell , Henri Termeer , Debjit Chattopadhyay , Mohit Bansal Citigroup , Bradley Campbell , Elizabeth Webster Goldman Sachs , Jeffreyp Castelli , Johnf Crowley , Salveen Richter , Daphne Quimi , Andrew Faughnan , Kristen Kluska , Kristen Kluska Cantor Fitzgerald , Jim Wilson , Aaron Welch Guggenheim , Jeff Castelli , Rossella Passero , Fabry Pompe , Anvita Cowen , John Crowley , Tazeen Ahmad , Mohit Bansal ,